PE20190372A1 - Comprimidos de disgregacion oral - Google Patents
Comprimidos de disgregacion oralInfo
- Publication number
- PE20190372A1 PE20190372A1 PE2018002028A PE2018002028A PE20190372A1 PE 20190372 A1 PE20190372 A1 PE 20190372A1 PE 2018002028 A PE2018002028 A PE 2018002028A PE 2018002028 A PE2018002028 A PE 2018002028A PE 20190372 A1 PE20190372 A1 PE 20190372A1
- Authority
- PE
- Peru
- Prior art keywords
- approximately
- compound
- total weight
- called
- patients
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- 208000019505 Deglutition disease Diseases 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- -1 among others Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 229960002528 ticagrelor Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/325—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil
- B65D75/327—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil and forming several compartments
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Composite Materials (AREA)
- Mechanical Engineering (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325584P | 2016-04-21 | 2016-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190372A1 true PE20190372A1 (es) | 2019-03-08 |
Family
ID=58640851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018002028A PE20190372A1 (es) | 2016-04-21 | 2017-04-20 | Comprimidos de disgregacion oral |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10729655B2 (enExample) |
| EP (2) | EP4417537A3 (enExample) |
| JP (2) | JP6960941B2 (enExample) |
| KR (2) | KR102392347B1 (enExample) |
| CN (3) | CN107595789B (enExample) |
| AU (2) | AU2017253367B2 (enExample) |
| BR (1) | BR112018071440A2 (enExample) |
| CO (1) | CO2018012431A2 (enExample) |
| DK (1) | DK3445338T3 (enExample) |
| EA (1) | EA201892150A1 (enExample) |
| ES (1) | ES3014055T3 (enExample) |
| FI (1) | FI3445338T3 (enExample) |
| HR (1) | HRP20250204T1 (enExample) |
| HU (1) | HUE070095T2 (enExample) |
| IL (1) | IL262312B (enExample) |
| LT (1) | LT3445338T (enExample) |
| MA (1) | MA44720B1 (enExample) |
| PE (1) | PE20190372A1 (enExample) |
| PH (1) | PH12018502226A1 (enExample) |
| PL (1) | PL3445338T3 (enExample) |
| PT (1) | PT3445338T (enExample) |
| RS (1) | RS66536B1 (enExample) |
| SG (2) | SG10202107682QA (enExample) |
| SI (1) | SI3445338T1 (enExample) |
| SM (1) | SMT202500081T1 (enExample) |
| WO (1) | WO2017182589A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111450067A (zh) * | 2019-01-18 | 2020-07-28 | 北京万全德众医药生物技术有限公司 | 一种替格瑞洛分散片及其制备方法 |
| CN109700773B (zh) * | 2019-03-01 | 2021-03-16 | 石药集团中奇制药技术（石家庄）有限公司 | 一种替格瑞洛制剂组合物及其制备方法 |
| JP7657041B2 (ja) | 2020-08-19 | 2025-04-04 | アストラゼネカ・アクチエボラーグ | 併用療法 |
| CN114712317A (zh) * | 2021-01-04 | 2022-07-08 | 弘和制药有限公司 | 一种替格瑞洛药物组合物及其制备方法和其应用 |
| US20220387328A1 (en) * | 2021-06-04 | 2022-12-08 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Dosage form for nicotine replacement therapy |
| WO2023057879A1 (en) * | 2021-10-04 | 2023-04-13 | Neurim Pharmaceuticals (1991) Ltd. | Methods and products for treating subjects with autism spectrum disorders |
| CN120129530A (zh) | 2022-10-28 | 2025-06-10 | 阿斯利康(瑞典)有限公司 | 以40mg至240mg的剂量用于在治疗缺血事件中使用的重组腺苷三磷酸双磷酸酶蛋白 |
| CN116370423B (zh) * | 2023-02-28 | 2024-11-12 | 天津力生制药股份有限公司 | 一种替格瑞洛口腔崩解片及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB516834A (en) * | 1937-12-23 | 1940-01-12 | Charles Alexandre Nicolle | Improvements in or relating to packaging |
| DE2246013A1 (de) | 1972-09-20 | 1974-03-28 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von poroesen tabletten |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| GB0013407D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
| ES2268020T3 (es) * | 2001-05-10 | 2007-03-16 | Astellas Pharma Inc. | Comprimidos de disgregacion rapida de la cavidad oral y proceso para producir los mismos. |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| CN2717851Y (zh) | 2004-05-14 | 2005-08-17 | 重庆康刻尔制药有限公司 | 一种药品包装板 |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| CN102058889A (zh) * | 2010-11-05 | 2011-05-18 | 王定豪 | 包含抗凝血类药物的分散片及其应用 |
| FR2968992B1 (fr) | 2010-12-16 | 2013-02-08 | Sanofi Aventis | Comprime pharmaceutique orodispersible a base de zolpidem |
| US20130160408A1 (en) | 2011-12-22 | 2013-06-27 | Gregor N. Neff | Blister Pack and Method |
| WO2013115171A1 (ja) | 2012-02-03 | 2013-08-08 | 旭化成ケミカルズ株式会社 | 苦味マスク顆粒含有口腔内崩壊錠 |
| CZ2012705A3 (cs) * | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
| CN103964066B (zh) * | 2013-02-06 | 2017-09-19 | 李和伟 | 一种冻干赋型制剂的包装装置 |
| WO2015110952A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof |
| CN104650091B (zh) * | 2014-01-24 | 2016-10-05 | 福州乾正药业有限公司 | 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用 |
| EA201691582A1 (ru) * | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
-
2017
- 2017-04-20 CN CN201710898954.2A patent/CN107595789B/zh active Active
- 2017-04-20 ES ES17720055T patent/ES3014055T3/es active Active
- 2017-04-20 HR HRP20250204TT patent/HRP20250204T1/hr unknown
- 2017-04-20 PE PE2018002028A patent/PE20190372A1/es unknown
- 2017-04-20 IL IL262312A patent/IL262312B/en unknown
- 2017-04-20 EP EP24187449.4A patent/EP4417537A3/en active Pending
- 2017-04-20 SM SM20250081T patent/SMT202500081T1/it unknown
- 2017-04-20 EA EA201892150A patent/EA201892150A1/ru unknown
- 2017-04-20 EP EP17720055.7A patent/EP3445338B1/en active Active
- 2017-04-20 LT LTEPPCT/EP2017/059443T patent/LT3445338T/lt unknown
- 2017-04-20 US US16/095,090 patent/US10729655B2/en active Active
- 2017-04-20 RS RS20250181A patent/RS66536B1/sr unknown
- 2017-04-20 CN CN201780000516.8A patent/CN107530288B/zh active Active
- 2017-04-20 PL PL17720055.7T patent/PL3445338T3/pl unknown
- 2017-04-20 FI FIEP17720055.7T patent/FI3445338T3/fi active
- 2017-04-20 CN CN201710899077.0A patent/CN107595790B/zh active Active
- 2017-04-20 PT PT177200557T patent/PT3445338T/pt unknown
- 2017-04-20 DK DK17720055.7T patent/DK3445338T3/da active
- 2017-04-20 MA MA44720A patent/MA44720B1/fr unknown
- 2017-04-20 KR KR1020187033221A patent/KR102392347B1/ko active Active
- 2017-04-20 WO PCT/EP2017/059443 patent/WO2017182589A1/en not_active Ceased
- 2017-04-20 KR KR1020227013818A patent/KR102488486B1/ko active Active
- 2017-04-20 SG SG10202107682QA patent/SG10202107682QA/en unknown
- 2017-04-20 SG SG11201808996SA patent/SG11201808996SA/en unknown
- 2017-04-20 BR BR112018071440A patent/BR112018071440A2/pt not_active Application Discontinuation
- 2017-04-20 SI SI201731586T patent/SI3445338T1/sl unknown
- 2017-04-20 JP JP2018555237A patent/JP6960941B2/ja active Active
- 2017-04-20 HU HUE17720055A patent/HUE070095T2/hu unknown
- 2017-04-20 AU AU2017253367A patent/AU2017253367B2/en active Active
-
2018
- 2018-10-18 PH PH12018502226A patent/PH12018502226A1/en unknown
- 2018-11-19 CO CONC2018/0012431A patent/CO2018012431A2/es unknown
-
2020
- 2020-03-18 AU AU2020201930A patent/AU2020201930B2/en active Active
-
2021
- 2021-10-12 JP JP2021167539A patent/JP7254871B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190372A1 (es) | Comprimidos de disgregacion oral | |
| AR118108A2 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| MX2017001671A (es) | Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton. | |
| PE20170195A1 (es) | Composicion para tratar diabetes, que contiene un conjugado de analogo de insulina de accion prolongada y un conjugado de peptido insulinotropico de accion prolongada | |
| AR107391A1 (es) | Formulaciones / composiciones que comprenden un inhibidor de btk | |
| MX2017011270A (es) | Composiciones farmaceuticas de un inhibidor de tirosina cinasa de bruton. | |
| TNSN07341A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| AR087205A1 (es) | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas | |
| MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
| CO6640264A2 (es) | Combinación de gránulos cargados activos con activos adicionales | |
| CR20200057A (es) | Dihidrooxadiazinonas | |
| IN2015DN04311A (enExample) | ||
| WO2015155711A4 (en) | Immunosuppressant formulation | |
| MY174005A (en) | Swallowable n-acetylcysteine tablets | |
| TN2017000258A1 (en) | Pyrazolopyridinamines as mknk1 and mknk2 inhibitors | |
| MX2023001014A (es) | Composiciones farmaceuticas que comprenden venglustat. | |
| ZA201804098B (en) | Treatment of hand eczema | |
| WO2021151442A3 (en) | Methotrexate dosage form | |
| AR101116A1 (es) | Formas de dosificación farmacéuticas para administración oral | |
| MX2018013428A (es) | Composicion farmaceutica de comprimido en comprimido que comprende ciclofosfamida y capecitabina. | |
| AR132685A2 (es) | Formulaciones farmacéuticas de un inhibidor de tirosina quinasa de bruton | |
| DOP2016000078A (es) | Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio | |
| HRPK20120437B3 (hr) | Obložena tableta koja sadrži imatinib mesilat, naäśin njezine proizvodnje i primjena | |
| CO2019001110A2 (es) | Composición mejorada de teneligliptina y metformina y proceso para prepararla |